-
Jul 18, 2024, 07:50 AM
by
BOC Sciences is pleased to announce its new Scholarship Program aimed at supporting college students pursuing degrees in chemistry-related fields. This prestigious scholarship awards $1,000 annually to help these aspiring chemists achieve their academic goals and make a difference in the scientific community.
Full story
-
Jul 17, 2024, 08:06 AM
by
Sapio Sciences, the science-aware™ lab informatics platform, today announced the Sapio Sciences Partner Program. The program provides a growing partner ecosystem of technology vendors, services companies, and resellers with the tools, training, support, and marketing services to deliver solutions that empower scientists.
Full story
-
Jul 17, 2024, 05:00 AM
by
User Not Found
Bio-IT World | With the rising costs of pharmaceutical industry R&D, achieving breakthroughs in some of the hardest-to-treat diseases, such as cancer, is becoming increasingly expensive. This presents a major challenge to developers in bringing efficient, affordable treatments to patients. AstraZeneca and Tempus teamed up to create a framework that can gather insights, discover novel drug targets, and aim to develop therapeutics for the broader oncology community.
Full story
-
Jul 16, 2024, 08:43 AM
by
Intelliguard, a proven provider of medication management and data intelligence solutions, has unveiled its Mira Ecosystem, a reimagined product line of innovative and integrated solutions for hospitals and healthcare systems that support increased patient safety and operational efficiency.
Full story
-
Jul 16, 2024, 08:43 AM
by
IDT inks licensing agreement with SeQure Dx to support cell and gene therapy developers through all stages of their CRISPR-based therapeutic programs.
Full story
-
Jul 16, 2024, 08:43 AM
by
Avallano is launching ProtocolCopilot™, an innovative AI-driven clinical research protocol assistant designed to transform the way biopharmaceutical companies and clinical research sites manage and interact with complex clinical trial protocols.
Full story
-
Jul 16, 2024, 08:43 AM
by
Optibrium, a leading developer of software and AI solutions for drug discovery and molecular design, today announced the appointment of James Halle as Chief Commercial Officer (CCO). James brings extensive software experience in the pharma industry and will guide the commercial success of the company.
Full story
-
Jul 16, 2024, 05:00 AM
by
User Not Found
Bio-IT World | Artificial intelligence (AI) is the new frontier in biomedical research, with large language models changing the way science is done from writing code and brainstorming research ideas to helping do research and conducting literature reviews. In some of its latest applications, generative AI has been used in designing molecules with insights produced at a scale and speed not possible with traditional deep learning methods alone.
Full story
-
Jul 12, 2024, 08:46 AM
by
Full story
-
Jul 12, 2024, 05:00 AM
by
User Not Found
Bio-IT World | Training and validating intelligent automation systems for life sciences R&D purposes can undermine the business case. But the large language models (LLMs) used to power Generative AI (GenAI) is changing that and bolstering compliance, enabling on-the-fly data discovery, “in context” learning, and narrative extrapolation.
Full story
-
Jul 11, 2024, 07:44 AM
by
Synexa Life Sciences has announced its enrolment in the My Green Lab Certification Program.
Full story
-
Jul 11, 2024, 07:44 AM
by
Surfix Diagnostics alongside the Netherlands Cancer Institute (NKI) and CRCbioscreen, announced a collaboration aimed at enhancing colorectal cancer (CRC) screening methods.
Full story
-
Jul 11, 2024, 07:44 AM
by
https://www.zymoresearch.com/blogs/press-releases/omics-discovery-grant-launch
Apply for Zymo Research's Omics Discovery Grant for cutting-edge RNA-Seq tools worth $4000.
Full story
-
Jul 10, 2024, 06:48 AM
by
DoseMe, a leading provider of model-informed precision dosing (MIPD), announced today it has earned certified status by HITRUST for information security. HITRUST Risk-based, 2-year (r2) Certification demonstrates that the organization’s DoseMeRX has met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk. This achievement places DoseMe in an elite group of organizations worldwide that have earned this certification. By including federal and state regulations, standards, and frameworks and incorporating a risk-based approach, the HITRUST Assurance Program helps organizations address security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls. DoseMe remains the only model informed precision dosing platform to achieve the r2 Certification.
Full story
-
Jul 10, 2024, 06:48 AM
by
The first-of-its-kind collaboration combines personalized genetic insights with evidence-based treatments to provide accessible and effective obesity care for women
Full story
-
Jul 10, 2024, 06:48 AM
by
Full story
-
Jul 10, 2024, 06:48 AM
by
Pascal Piedbois, MD, PhD joins One2Treat as Chief Medical Officer to advance patient-centric innovation in clinical trial design and market access.
One2Treat reflects patient priorities in a single multi-facet treatment assessment, reducing trial sample size and accelerating patient access to new treatments.
Full story
-
Jul 10, 2024, 06:48 AM
by
SMi Systems announces the appointment of Dr Stefan Hamill as its Vice President of Strategy. Dr Hamill was formerly a senior analyst at investment banks Numis (now Deutsche Numis) and Peel Hunt, both of which he helped transform into #1 ranked franchises in UK Life Sciences.
Full story
-
Jul 10, 2024, 05:00 AM
by
User Not Found
Bio-IT World | Until recently, all the available therapeutic options for treating Alzheimer’s disease were designed to reduce symptoms rather than address causes of the disease. But with two beta-amyloid antibodies now approved by the U.S. Food and Drug Administration, and tau-targeting agents in clinical trials, hopes are rising that Alzheimer’s progression can be delayed if not stopped.
Full story
-
Jul 9, 2024, 16:22 PM
by
User Not Found
Bio-IT World | Illumina has acquired Fluent BioSciences, developer of an emerging and highly differentiated single-cell technology. Fluent Biosciences is now a wholly owned subsidiary of Illumina and was acquired with cash on hand.
Full story